Cancer chemotherapy-induced diarrhoea and constipation: mechanisms of damage and prevention strategies

  title={Cancer chemotherapy-induced diarrhoea and constipation: mechanisms of damage and prevention strategies},
  author={Rachel Gibson and Dorothy Keefe},
  journal={Supportive Care in Cancer},
BackgroundDiarrhoea and constipation are common toxicities of chemotherapy, and both are poorly understood. They are manifestations of alimentary mucositis, a condition which affects the entire gastrointestinal tract.DiscussionThe absolute percentage of patients that have diarrhoea or constipation as a result of their treatment has yet to be fully defined, although general estimates place 10% of patients with advanced cancer as being afflicted. Although there has been some major progress in… 

Chemotherapy-Induced Constipation and Diarrhea: Pathophysiology, Current and Emerging Treatments

Identification of potential targets for novel therapies to alleviate chemotherapy-induced toxicity is essential to improve clinical outcomes and quality of life amongst cancer sufferers.

Anti-Colorectal Cancer Chemotherapy-Induced Diarrhoea: Current Treatments and Side-Effects

This work provides a review of chemotherapy-induced diarrhoea, current management guidelines, and shortcomings of current treatments as well as emerging and already existing anti-diarrhoeal treatments potentially suitable for CID.

Emerging drugs for chemotherapy-induced mucositis

There are many agents in varying stages of development for chemotherapy-induced mucositis, and the field is complicated by the question of whether treatments should be developed as drugs or as medical foods, and whether the burden of proof of efficacy and safety should be different.

Gastrointestinal consequences of cancer treatment and the wider context: A bad gut feeling

As the understanding of consequences of cancer treatments continues to emerge and encompass a wide variety of specialties, a holistic, multifaceted and multidisciplinary approach is required to manage those consequences long-term.

Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: the role of inflammation.

The basic mechanisms involved in the promotion of immunogenic cell death and its relevance in the treatment of colorectal cancer are reviewed and the impact of CID on patient outcomes and therapeutic strategies to prevent or minimise the effect of GI toxicity and mucositis are discussed.

Chemotherapy-induced modifications to gastrointestinal microflora: evidence and implications of change.

A review will explore the potentially important relationship between intestinal microflora and the subsequent development of chemotherapy-induced mucositis.

VSL#3 probiotic treatment reduces chemotherapy-induced diarrhoea and weight loss

VSL#3 is effective at preventing severe diarrhoea following chemotherapy with irinotecan and therefore has potential to be used clinically by cancer patients.



Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhoea.

Constipation in advanced cancer patients

Constipation is a frequent, distressing, and underestimated complication in patients with advanced cancer. It may develop from general disturbances that may or may not be cancer related, but the use

Effect of high-dose chemotherapy on intestinal permeability in humans.

It is concluded that chemotherapy given for malignant disease is associated with a transient abnormality in intestinal sugar permeability, which peaks at 7 days after treatment and is composed of both mono- and di-saccharide absorption abnormalities.

Mucositis: Its Occurrence, Consequences, and Treatment in the Oncology Setting.

Mucositis induced by antineoplastic drugs is an important, dose-limiting, and costly side effect of cancer therapy and can also have a significant economic cost in the autologous and allogeneic bone marrow transplant settings for hematologic malignancies.

Management of Chemotherapy-Induced Adverse Effects in the Treatment of Colorectal Cancer

Supportive measures for alleviation of the adverse effects of fluorouracil, raltitrexed, irinotecan and oxaliplatin, respectively, are described, based on study results.

Overview of chemotherapy-induced diarrhea.

  • C. Viele
  • Medicine
    Seminars in oncology nursing
  • 2003
Through ongoing, regular patient contact, the oncology nurse is uniquely situated to monitor patients for the development of CID, assess its severity, and provide guidance to the health care team on the patient's status.

Control of chemotherapy-induced diarrhoea with octreotide in patients receiving 5-fluorouracil.

The biological basis for the attenuation of mucositis: the example of interleukin-11

Interleukin-11, a pleotropic cytokine, has a range of activities which are potentially relevant to mucositis and has been used successfully to modify the development, severity and course of mucosiositis in an animal model which closely mimics the equivalent human condition.

Management of acute cancer treatment-induced diarrhea.

Whatever therapy is chosen, the goal must be to quickly control this debilitating and potentially life-threatening side effect so that primary chemotherapy and/or radiation therapy may be resumed and completed.